NFKB1 and COVID-19: Animal and clinical studies on SARS-CoV-2 have revealed that blockage of the transcription factor kappa-B (NF-κB) can reduce IL-6 expression, and can be a potential target to treat critically ill patients with COVID-19 [108,109].